{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:56:09Z","timestamp":1782950169153,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004824","name":"Dansk Nefrologisk Selskab","doi-asserted-by":"publisher","award":["DKK 25,000"],"award-info":[{"award-number":["DKK 25,000"]}],"id":[{"id":"10.13039\/501100004824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","award":["DKK 1,700,000"],"award-info":[{"award-number":["DKK 1,700,000"]}],"id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020219","name":"Helen og Ejnar Bj\u00f8rnows Fond","doi-asserted-by":"publisher","award":["DKK 50,000"],"award-info":[{"award-number":["DKK 50,000"]}],"id":[{"id":"10.13039\/501100020219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xkme.2025.101136","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:38:08Z","timestamp":1760143088000},"page":"101136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-0814","authenticated-orcid":false,"given":"Sarah","family":"Kelddal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik L.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla L.","family":"Duus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis B.","family":"Nygaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilde","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"Mose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon W.","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mette","family":"Hvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xkme.2025.101136_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1345\/aph.1R530","article-title":"Prophylaxis of thromboembolic events in patients with nephrotic syndrome","volume":"47","author":"Pincus","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.xkme.2025.101136_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.xkme.2025.101136_bib3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00001721-200210000-00006","article-title":"Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome","volume":"13","author":"Malyszko","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.xkme.2025.101136_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.thromres.2021.02.007","article-title":"Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy","volume":"201","author":"Waller","year":"2021","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.xkme.2025.101136_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ki.1985.149","article-title":"Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome","volume":"28","author":"Llach","year":"1985","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2025.101136_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000448628","article-title":"Venous thromboembolism in primary nephrotic syndrome - is the risk high enough to justify prophylactic anticoagulation?","volume":"135","author":"Rankin","year":"2017","journal-title":"Nephron"},{"issue":"6","key":"10.1016\/j.xkme.2025.101136_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102162","article-title":"Thromboembolism in nephrotic syndrome: controversies and uncertainties","volume":"7","author":"Parker","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"4S","key":"10.1016\/j.xkme.2025.101136_bib8","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.xkme.2025.101136_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255009","article-title":"Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome-A retrospective observational study","volume":"16","author":"Welander","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.xkme.2025.101136_bib10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2215\/CJN.07190713","article-title":"Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101136_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000188355","article-title":"Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin","volume":"69","author":"Rostoker","year":"1995","journal-title":"Nephron"},{"issue":"23","key":"10.1016\/j.xkme.2025.101136_bib12","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.3390\/jcm10235709","article-title":"Anti-Xa activity of enoxaparin for prevention of venous thromboembolism in severe nephrotic syndrome-a single center prospective study","volume":"10","author":"Matyjek","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.xkme.2025.101136_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","article-title":"Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications","volume":"20","author":"Kelddal","year":"2019","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2025.101136_bib14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imj.16227","article-title":"Efficacy and safety of prophylactic anticoagulation in patients with primary nephrotic syndrome: a systematic review and meta-analysis","volume":"54","author":"De Pascali","year":"2024","journal-title":"Intern Med J"},{"key":"10.1016\/j.xkme.2025.101136_bib15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.xkme.2025.101136_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000188703","article-title":"Pharmacokinetic study of the low-molecular-weight heparin fraxiparin in patients with nephrotic syndrome","volume":"71","author":"Alhenc-Gelas","year":"1995","journal-title":"Nephron"},{"issue":"9921","key":"10.1016\/j.xkme.2025.101136_bib17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.xkme.2025.101136_bib18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.xkme.2025.101136_bib19","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2165\/11635730-000000000-00000","article-title":"New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function","volume":"72","author":"Poulsen","year":"2012","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.xkme.2025.101136_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ekir.2018.02.010","article-title":"Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome","volume":"3","author":"Sexton","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1016\/j.xkme.2025.101136_bib21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.xkme.2025.101136_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ekir.2019.12.001","article-title":"A systematic review of prophylactic anticoagulation in nephrotic syndrome","volume":"5","author":"Lin","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.xkme.2025.101136_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.ajkd.2022.09.011","article-title":"Pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome: findings from a phase 1a trial","volume":"81","author":"Derebail","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.xkme.2025.101136_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000540107","article-title":"Rivaroxaban for thromboembolism prophylaxis in patients with nephrotic syndrome: a single-arm, prospective study","volume":"10","author":"Wei","year":"2024","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"10.1016\/j.xkme.2025.101136_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12882-022-02929-x","article-title":"Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases","volume":"23","author":"Kelddal","year":"2022","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2025.101136_bib26","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1055\/a-1920-6224","article-title":"Apixaban prophylactic anticoagulation in patients with nephrotic syndrome","volume":"6","author":"Van Meerhaeghe","year":"2022","journal-title":"TH Open"},{"issue":"7","key":"10.1016\/j.xkme.2025.101136_bib27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1055\/s-0041-1727116","article-title":"Thrombin: a pivotal player in hemostasis and beyond","volume":"47","author":"Larsen","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.xkme.2025.101136_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.thromres.2021.11.017","article-title":"Corrigendum to \"Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients\" [Thromb. Res. 186 2020. 80-85]","volume":"216","author":"Lundbech","year":"2022","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.xkme.2025.101136_bib29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2165\/00003495-199652020-00011","article-title":"Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders","volume":"52","author":"Dunn","year":"1996","journal-title":"Drugs"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:10:10Z","timestamp":1773328210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525001724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2590059525001724"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101136","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101136"}}